Springer Drug Resistance in Cancer Therapy: 48 (Cancer Treatment and Research, 48)

Product Description Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfor tunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes that aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion: first, by dividing the oncology literature into specific subdivisions such as lung can cer, genitourinary cancer, and pediatric oncology; second, by asking emi nent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more. Review `This book would be a helpful text for basic researchers, clinical investigators, and medical housestaff. It is well written and can be read in a relatively short period. ' Breast Cancer Research and Treatment, 19, 1991 ` The book is an exciting survey of the potential application of laboratory data. It is a good example of interdisciplinary research collaboration. It is recommended reading for those engaged in the development of new treatment strategies. ' Oncology, 48/1